News
OCRFA’s Response to Trump Administration’s Birth Control Coverage Rollback
(Oct…
Studies Show that Current Chemotherapy Dosage is Still Best Option for Epithelial Ovarian Cancer
(September 15, 2017) Two studies just confirmed that, depending on one’s genetic background, the standard treatment for epithelial ovarian cancer is most likely the best option…
Folonari Wines Partners with OCRFA
(September 8, 2017) Through its ongoing ‘AMORE, ITALIA, FOLONARI’ campaign, Folonari Wines has partnered this year with Ovarian Cancer Research Alliance…
The Link Between Chemotherapy Resistance and a Tumor’s BRCA1/2 Mutations
(September 5, 2017) Researchers at the University of Pennsylvania recently uncovered a link between one’s resistance to common types of chemotherapy and one’s tumor BRCA1/2 mutation status…
Share Your #OvarianStory to Raise Awareness
Every 23 minutes another woman is diagnosed with ovarian cancer. All of them have a story. This September, we’re inviting you to share your #OvarianStory…
Newk’s Eatery “Joins the Fight” Against Ovarian Cancer with Fundraiser
(August 31, 2017) In answer to the persisting need for a cure to one of the deadliest diseases facing women today, Newk’s Eatery is calling on partners and patrons across its 115 restaurants to “Join the Fight” against ovarian cancer…
Genetic Testing Rates Found to be Low in Women With A History of Breast or Ovarian Cancer
(August 22, 2017) The Journal of Clinical Oncology recently published a study about the unmet need of genetic testing in women with breast and ovarian cancer…
FDA Approves New Indication and Formulation for Olaparib
(August 21, 2017) The US Food and Drug Administration (FDA) has granted full approval to olaparib tablets (Lynparza, AstraZeneca) for use as maintenance therapy for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal…
Age When Giving Birth and Oral Contraceptives Influence One’s Risk of Ovarian Cancer
(August 9, 2017) The International Journal of Cancer recently published an article on preliminary findings for two factors that influence one’s risk of ovarian cancer, namely the age at which a woman gives birth and the age at which she starts…
Updated Patient Resources for Ovarian Cancer from the National Comprehensive Cancer Network
(July 31, 2017) The National Comprehensive Cancer Network (NCCN), has updated and published guidelines for patients with ovarian cancer. There are two parts to the resource guide: The Guidelines for Patients and Quick Guides…
OCRFA Funded Project Has Breakthrough on Therapeutic Approach for Rare Ovarian Cancer
(July 27, 2017) Earlier this week, in Nature Cell Biology, researchers at The Wistar Institute published their findings about a few strategies to treat clear cell carcinoma…
Leading ovarian cancer organization announces 2017 honorees
Largest private funder of ovarian cancer research recognizes top researchers and community leaders NEW YORK — Today, Ovarian Cancer Research Alliance (OCRFA), the nation’s leading ovarian cancer research, advocacy and patient support…